Budesonide/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 11, 2015, Pages 1242-1249

  Bergeron, Anne ^a,b   Chevret, Sylvie ^a,b   Chagnon, Karine ^a,c   Godet, Cendrine ^d   Bergot, Emmanuel ^e   De Latour, Régis Peffault ^a   Dominique, Stéphane ^f   De Revel, Thierry ^g   Juvin, Karine ^h   Maillard, Natacha ^d   Reman, Oumedaly ^e   Contentin, Nathalie ⁱ   Robin, Marie ^a   Buzyn, Agnès ^j   Socié, Gérard ^a   Tazi, Abdellatif ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PARIS DESCARTES UNIVERSITY   (France)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f HÔPITAL CHARLES NICOLLE   (France)

^g PERCY MILITARY HOSPITAL   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ CENTRE HENRI BECQUEREL   (France)

^j HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

Inhaled long acting bronchodilator and steroids; Lung chronic graft versus host disease; Obstructive lung disease

Indexed keywords

BUDESONIDE; FORMOTEROL; PLACEBO; POSACONAZOLE; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENTION TO TREAT ANALYSIS; LEG EDEMA; LICHEN (DISEASE); MALE; METERED DOSE INHALER; MULTICENTER STUDY; MUSCLE CRAMP; OROPHARYNX CANDIDIASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SUPRAVENTRICULAR PREMATURE BEAT; TACHYCARDIA; TENDINITIS; THORAX PAIN; TINNITUS; TREMOR; VOMITING; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; BRONCHIOLITIS OBLITERANS; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84930451426     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201410-1818OC     Document Type: Article

References (26)

1. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, Clark JG. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003;168:208-214.
2. Kuzmina Z, Krenn K, Petkov V, Körmöczi U, Weigl R, Rottal A, Kalhs P, Mitterbauer M, Ponhold L, Dekan G, et al. CD19(1)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood 2013;121:1886-1895.
3. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003;9:657-666.
4. Bergeron A, Godet C, Chevret S, Lorillon G, Peffault de Latour R, de Revel T, Robin M, Ribaud P, SociéG, Tazi A. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant 2013;48:819-824.
5. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff D. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011;46: 1283-1295.
6. Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): firstline and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010;16:1611-1628.
7. Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee SJ, Moravec CK, Chien JW. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 2011;46:1369-1373.
8. Chan CK, Hyland RH, Hutcheon MA, Minden MD, Alexander MA, Kossakowska AE, Urbanski SJ, Fyles GM, Fraser IM, Curtis JE, et al. Small-airways disease in recipients of allogeneic bone marrow transplants: an analysis of 11 cases and a review of the literature. Medicine (Baltimore) 1987;66:327-340.
9. Philit F, Wiesendanger T, Archimbaud E, Mornex JF, Brune J, Cordier JF. Post-transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995;8:551-558.
10. SociéG, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, Korthof E, Weis J, Levy V, Tichelli A; Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003;101:3373-3385.
11. Duarte RF, Greinix H, Rabin B, Mitchell SA, Basak G, Wolff D, Madrigal JA, Pavletic SZ, Lee SJ. Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force. Bone Marrow Transplant 2014;49:49-54.
12. Bergeron A, Belle A, Chevret S, Ribaud P, Devergie A, Esperou H, Ades L, Gluckman E, SociéG, Tazi A. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:547-553.
13. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945-956.
14. Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, Heim D, Passweg JR, Tichelli A, Bubendorf L, et al. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:973-980.
15. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26: 948-968.
16. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85(Suppl B):25-31; discussion 33-27.
17. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol 2006;59:1102-1109.
18. Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ 2010;340:c2073.
19. Bender R, Lange S. Adjusting for multiple testing: when and how? J Clin Epidemiol 2001;54:343-349.
20. Bacigalupo A, Chien J, Barisione G, Pavletic S. Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. Semin Hematol 2012;49:15-24.
21. Martin PJ, Chien JW. What we know and mostly do not know about bronchiolitis obliterans syndrome. Bone Marrow Transplant 2012;47:1-4.
22. Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr Pharm Des 2006;12:3261-3279.
23. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;8:CD006826.
24. Barisione G, Bacigalupo A, Crimi E, Brusasco V. Acute bronchodilator responsiveness in bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation. Chest 2011;139:633-639.
25. Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25-75% and FEF75% does not contribute to clinical decision making. Eur Respir J 2014;43:1051-1058.
26. Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 2012;9:48-55.